By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Asterias Biotherapeutics 

6300 Dumbarton Circle

Fremont  California  94555  U.S.A.
Phone: 510-456-3800 Fax: n/a



Company News
Asterias Biotherapeutics Announces Successful Commencement Of Operations At New GMP Manufacturing Facility For AST-OPC1 1/9/2017 9:57:17 AM
Ryan Chavez Appointed Chief Financial Officer Of Asterias Biotherapeutics 11/17/2016 8:31:30 AM
Asterias Biotherapeutics Reports Third Quarter Results And Accelerating Enrollment Of AST-OPC1 SCiStar Phase 1/2a Study 11/15/2016 11:09:47 AM
Asterias Biotherapeutics Announces Treatment Of First Spinal Cord Injury Patient With Maximum Dose Of AST-OPC1 In SCiStar Clinical Trial 11/9/2016 11:31:30 AM
Asterias Biotherapeutics To Report Third Quarter Results On November 14, 2016 11/4/2016 9:11:37 AM
Asterias Biotherapeutics Announces Dosing Of First Patient In New SCiSTAR Clinical Trial Cohort Testing AST-OPC1 In An Expanded Cervical Spinal Cord Injury Patient Population 9/27/2016 7:42:02 AM
BioTime (BTX) Affiliate, Asterias Biotherapeutics, Announced Positive Interim Efficacy Data From Trial In Patients With Complete Cervical Spinal Cord Injuries 9/16/2016 11:38:44 AM
Asterias Biotherapeutics AST-OPC1 Treatment For Spinal Cord Injury Patients Shown To Help Patients Paralyzed From The Neck Down Regain Function In The Arms And Hands 9/14/2016 8:32:20 AM
AiVita CEO Comments On Recent Milestone Achievements In Asterias Biotherapeutics' Scistar Trial For Spinal Cord Injury 9/13/2016 11:38:22 AM
Asterias Biotherapeutics Announces AST-OPC1 SCiSTAR Study Investigator Charles Y. Liu, MD, PhD, And Director, USC Neurorestoration Center, To Discuss Interim Data On Conference Call On September 14, 2016 9/13/2016 9:19:19 AM